

RESEARCH ARTICLE

Vacuolar proton-translocating ATPase is required for antifungal resistance and virulence of *Candida glabrata*

Asuka Minematsu^{1,2}, Taiga Miyazaki^{1,2*}, Shintaro Shimamura², Hiroshi Nishikawa^{2a}, Hironobu Nakayama³, Takahiro Takazono^{1,2}, Tomomi Saijo², Kazuko Yamamoto², Yoshifumi Imamura², Katsunori Yanagihara⁴, Shigeru Kohno², Hiroshi Mukae², Koichi Izumikawa¹

1 Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, **2** Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan, **3** Faculty of Pharmaceutical Sciences, Suzuka University of Medical Sciences, Mie, Japan, **4** Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

✉ Current address: Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd, Tokushima, Japan

* taiga-m@nagasaki-u.ac.jp



OPEN ACCESS

Citation: Minematsu A, Miyazaki T, Shimamura S, Nishikawa H, Nakayama H, Takazono T, et al. (2019) Vacuolar proton-translocating ATPase is required for antifungal resistance and virulence of *Candida glabrata*. PLoS ONE 14(1): e0210883. <https://doi.org/10.1371/journal.pone.0210883>

Editor: Alix Therese Coste, Institute of Microbiology, SWITZERLAND

Received: August 26, 2018

Accepted: January 3, 2019

Published: January 23, 2019

Copyright: © 2019 Minematsu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was partially supported by the Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED) (<https://www.amed.go.jp/en/program/list/01/06/002.html>) (grant number JP18fk0108008 to T.M. and S.K.). The funder had no role in study design, data collection and analysis, decision to publish, or

Abstract

Vacuolar proton-translocating ATPase (V-ATPase) is located in fungal vacuolar membranes. It is involved in multiple cellular processes, including the maintenance of intracellular ion homeostasis by maintaining acidic pH within the cell. The importance of V-ATPase in virulence has been demonstrated in several pathogenic fungi, including *Candida albicans*. However, it remains to be determined in the clinically important fungal pathogen *Candida glabrata*. Increasing multidrug resistance of *C. glabrata* is becoming a critical issue in the clinical setting. In the current study, we demonstrated that the plecomacrolide V-ATPase inhibitor bafilomycin B₁ exerts a synergistic effect with azole antifungal agents, including fluconazole and voriconazole, against a *C. glabrata* wild-type strain. Furthermore, the deletion of the *VPH2* gene encoding an assembly factor of V-ATPase was sufficient to interfere with V-ATPase function in *C. glabrata*, resulting in impaired pH homeostasis in the vacuole and increased sensitivity to a variety of environmental stresses, such as alkaline conditions (pH 7.4), ion stress (Na⁺, Ca²⁺, Mn²⁺, and Zn²⁺ stress), exposure to the calcineurin inhibitor FK506 and antifungal agents (azoles and amphotericin B), and iron limitation. In addition, virulence of *C. glabrata* $\Delta vph2$ mutant in a mouse model of disseminated candidiasis was reduced in comparison with that of the wild-type and *VPH2*-reconstituted strains. These findings support the notion that V-ATPase is a potential attractive target for the development of effective antifungal strategies.

Introduction

Invasive candidiasis is one of the most frequent fungal infections among a wide spectrum of immunocompromised patients, with the in-hospital mortality rates reported to be as high as 20–40% even among patients who receive antifungal therapy [1]. The therapeutic options

preparation of the manuscript. There was no additional external funding received for this study.

Competing interests: The authors have declared that no competing interests exist.

currently available to treat invasive candidiasis are limited to only four classes of antifungal agents: azoles, echinocandins, polyenes, and fluoropyrimidines. Further, the incidence rates of candidemia caused by non-*albicans* *Candida* species are increasing and antifungal resistance of these species has emerged as a serious problem in clinical practice [1–3]. The rise of multi-drug resistance with unfavorable therapeutic outcome among *Candida glabrata* infections became a critical healthcare issue in the last decade [4–6]. Therefore, the development of novel antifungal strategies is urgently needed.

Recent studies highlight vacuolar proton-translocating ATPase (V-ATPase) as an attractive target for drug discovery (reviewed in [7]). V-ATPase is an ATP-driven proton pump present in the endomembranes of all eukaryotic organisms [8, 9]. In particular, this proton pump is present in fungal vacuolar membranes, where it plays an important role in the maintenance of intracellular ion homeostasis by maintaining acidic pH within cell [10–12]. The V-ATPase is composed of 14 subunits that form two domains, a membrane-integral V_0 domain and a cytoplasmic V_1 domain; and assembly factors, including Vph2 (Vma12), Vma21, Vma22, and Pkr1, are required for the assembly of a functional yeast V-ATPase [9, 13–15]. In *Saccharomyces cerevisiae*, V-ATPase synthesis and assembly are lost upon deletion of *VPH2*, leading to changes in ion sensitivity, including calcium sensitivity [16]. Previously, we demonstrated that V-ATPase also plays an important role in endogenous and exogenous oxidative stress response by regulating the expression and activity levels of the superoxide dismutase Sod2 and catalase Cta1, respectively, in *C. glabrata* [17].

Previous studies with mutant strains of *Histoplasma capsulatum*, *Cryptococcus neoformans*, and *C. albicans* lacking specific subunits of V-ATPase demonstrated that loss of V-ATPase function leads to vacuolar alkalinization and attenuation of *in vivo* virulence [18–21]. However, the link between V-ATPase function and virulence in *C. glabrata* has not been reported. In the current study, we investigated the effects of V-ATPase defect in *C. glabrata* on responses to various environmental stresses, antifungal resistance, and virulence.

Materials and methods

Strains, culture conditions, and compounds

C. glabrata strain CBS138 [22] was used as a wild-type control. *C. glabrata* $\Delta vph2$ deletion mutant lacking the entire *VPH2* open reading frame (NCBI accession no.: XP_448720, *Candida* genome database ID: CAGL0K11594g) and a *VPH2*-reconstituted strain, in which an intact *VPH2* was reintroduced at the native locus in the genome of the $\Delta vph2$ mutant, were constructed previously [17]. *C. glabrata* cells were propagated in yeast peptone dextrose (YPD) medium [1% (wt/vol) yeast extract, 2% (wt/vol) peptone, and 2% (wt/vol) glucose] or synthetic complete medium (SC) [0.67% (wt/vol) yeast nitrogen base with amino acids and 2% (wt/vol) glucose] at 30°C, unless otherwise specified. Media were solidified by the addition of 1.5% (wt/vol) agar. Fluconazole, voriconazole, amphotericin B, and FK506 were purchased from Sigma-Aldrich (St. Louis, MO). Bafilomycin B₁ was purchased from Santa Cruz Biotechnology (Dallas, TX). Desferrioxamine (DFO) was purchased from EMD Chemicals (San Diego, CA) and bathophenanthroline disulfonate (BPS) was from MP Biomedicals (Solon, OH). Voriconazole, bafilomycin B₁, and FK506 were dissolved in dimethyl sulfoxide and other compounds were dissolved in distilled water. Cell growth was not affected by exposure to the quantities of dimethyl sulfoxide used in the current study.

Drug susceptibility assays

Susceptibility to fluconazole, voriconazole, and the V-ATPase inhibitor bafilomycin B₁, alone or in combination, was examined by using broth microdilution test, essentially according to

the Clinical and Laboratory Standards Institute (CLSI) M27-S4 protocol [23] and the previous report [24] with minor modifications. Briefly, *C. glabrata* cells were incubated in SC at 35°C for 48 h. The minimum drug concentration that inhibited cell growth by more than 80% relative to drug-free control was defined as the minimum inhibitory concentration (MIC). Fractional inhibitory concentration (FIC) was calculated by using the following formula: FIC for drug A = (MIC of drug A in combination with drug B)/(MIC of drug A alone). The sum of FIC for drug A and FIC for drug B was defined as the FIC index (FICI). Drug interaction was classified as synergistic if FICI was ≤ 0.5 [25].

Spot dilution test was performed as described previously [26]. Briefly, the density of logarithmic-phase cultures in SC was adjusted to the concentration of 2×10^7 cells/ml. Serial 10-fold dilutions in SC were then prepared, and 5 μ l of each dilution was spotted onto SC plates containing the test compound at the desired concentrations. Plates were incubated at 30°C for 48 h and photographed.

All sensitivity tests were performed on at least three separate occasions to ensure reproducibility.

Staining of fungal cells

Vacuolar staining with the styryl dye *N*-(3-triethylammoniumpropyl)-4-(6-(4-(diethylamino)phenyl)hexatrienyl)pyridinium dibromide (FM4-64; Thermo Fisher Scientific, Molecular Probes, Eugene, OR) and the pH-sensitive fluorophore 2*N*,7*N*-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM; Thermo Fisher Scientific, Molecular Probes) was performed as described previously [27, 28] with few modifications. Briefly, logarithmic-phase cells of *C. glabrata* were washed and resuspended in SC broth (pH 5.0). FM4-64 was added to cell suspensions (final concentration: 5 μ M) and the mixtures were incubated at 30°C for 15 min to stain vacuole membranes. Cells were washed in SC with agitation for 90 min and resuspended in SC. BCECF-AM was added to cell suspensions (final concentration: 18 μ M) and incubated at 30°C for 60 min. Cells were washed twice in SC, and microscopic examination was performed immediately after washing. Images were acquired using a Carl Zeiss LSM780 confocal laser-scanning microscope and processed using ZEN 2011 software (Carl Zeiss, Jena, Germany). The excitation and emission parameters were as follows: 560 and 605 nm, respectively, for FM4-64; and 470 and 535 nm, respectively, for BCECF-AM.

Virulence assay

Specific pathogen-free 8-week-old female BALB/c mice, weighing approximately 20 g, were purchased from Charles River Laboratories Japan (Yokohama, Japan). All mice had free access to food and water and were housed in a light- and temperature-controlled room at the Biomedical Research Center, Life Science Support Center, Nagasaki University. The health status of all mice was monitored at least daily throughout the experiments. All animal experiments were performed in full compliance with the Guide for the Care and Use of Laboratory Animals [29] and all institutional regulations and guidelines for animal experimentation, after pertinent review and approval by the Institutional Animal Care and Use Committee of Nagasaki University (protocol number 1407281164).

Logarithmic-phase cells of *C. glabrata* wild-type, Δ *vph2*, and *VPH2*-reconstituted strains were harvested, washed, and resuspended in sterile saline, and cell density was adjusted to 4×10^8 cells/ml. The actual colony forming units (CFUs) used were confirmed by plating serial dilutions of the cell suspensions on YPD plates and incubating at 30°C overnight. Mice ($n = 7$ for wild-type, $n = 9$ for Δ *vph2*, and $n = 8$ for Δ *vph2* + *VPH2*, per experiment) were inoculated with 0.2 ml of each cell suspension via the lateral tail vein. Mice were euthanized by carbon

dioxide-induced asphyxia 7 d after the injection, and the spleen, liver, and both kidneys were excised. The organs were homogenized in sterile saline using a Shake Master NEO (Bio Medical Science, Tokyo, Japan). The homogenates were appropriately diluted in sterile saline and plated on YPD agar. Colonies were counted after 48 h of incubation at 30°C and CFUs per organ were calculated. A *P*-value of <0.05 (Kruskal-Wallis test with Dunn's post-test) was considered to represent statistical significance.

Results

Synergistic effects of azoles and the V-ATPase inhibitor bafilomycin B₁ against *C. glabrata*

Azole antifungals, including fluconazole and voriconazole, inhibit the biosynthesis of ergosterol, the major component of fungal cell membrane, by targeting lanosterol 14 α -demethylase encoded by *ERG11* [30]. V-ATPase is pharmacologically inhibited by the plecomacrolide bafilomycin B₁, which binds to the V0 subunit of V-ATPase, and simultaneously interferes with ATP hydrolysis and proton transport [31, 32]. To examine the effect of bafilomycin B₁ on azole susceptibility of *C. glabrata* wild-type strain, we performed a checkerboard assay using serial 2-fold dilutions of the drugs. In the assay, MICs of fluconazole, voriconazole, and bafilomycin B₁ were determined to be >64, 4, and >32 μ g/ml, respectively (Fig 1). FIC indices of the combination of fluconazole and bafilomycin B₁, and the combination of voriconazole and bafilomycin B₁ were 0.375 and 0.313, respectively, indicating synergistic effects of these azoles and bafilomycin B₁ against *C. glabrata*.

Deletion of the V-ATPase assembly factor gene *VPH2* leads to impaired vacuole acidification in *C. glabrata*

To investigate the role of V-ATPase in *C. glabrata* in detail, we analyzed the phenotype of the Δ *vph2* mutant, by comparing it with that of the wild-type and *VPH2*-reconstituted strains. First, *C. glabrata* cells were incubated with FM4-64, which selectively stains yeast vacuolar membranes and may be detected by red fluorescence [33, 34]. The wild-type and *VPH2*-reconstituted strains exhibited the typical ring-staining pattern of the vacuole membrane, while FM4-64 accumulated within the vacuole lumen in the Δ *vph2* mutant (Fig 2). The impaired trafficking of FM4-64 to the vacuolar membrane in the Δ *vph2* mutant was consistent with




Fig 1. Synergistic effects of azole antifungals and the V-ATPase inhibitor bafilomycin B₁ against *C. glabrata* wild-type strain. Checkerboard assay was performed using serial 2-fold dilutions of drugs. (A) Data for the combination of fluconazole and bafilomycin B₁. (B) Data for the combination of voriconazole and bafilomycin B₁. Plates were incubated at 35°C for 48 h and the optical density at 600 nm (OD₆₀₀) was determined. The graphs are representative of three independent replicate experiments.

<https://doi.org/10.1371/journal.pone.0210883.g001>




Fig 2. Vacuole staining. Logarithmic-phase cells of *C. glabrata* were prepared in SC broth. Vacuolar membranes were first stained with FM4-64. After washing, the pH-sensitive fluorophore BCECF-AM was added to cell suspensions. Note the accumulation of FM4-64 and BCECF-AM within the vacuole lumen of the $\Delta vph2$ mutant. Scale bars, 5 μm . The images are representative of three independent replicate experiments.

<https://doi.org/10.1371/journal.pone.0210883.g002>

endocytosis defects demonstrated by *C. albicans vma* mutants [21] and *C. albicans* cells treated with fluconazole [28].

The cells were then labeled with the pH-sensitive fluorescent dye BCECF-AM. The dye labeled the vacuoles of the $\Delta vph2$ mutant but not those of the wild-type and *VPH2*-reconstituted strains (Fig 2). This indicated impaired vacuolar acidification in the $\Delta vph2$ mutant, as would be expected after loss of proton pump capacity.

Loss of *Vph2* results in increased fungal sensitivity to various environmental stresses

The phenotype of the $\Delta vph2$ mutant was further examined by spot dilution assays. In agreement with the notion of impaired vacuole acidification even under acidic conditions (Fig 2), the $\Delta vph2$ mutant exhibited a growth defect at pH 5.0 and was unable to grow at pH 7.4 (Fig 3). The $\Delta vph2$ mutant also displayed increased sensitivity to ion stress induced by excess of NaCl, CaCl₂, MnCl₂, and ZnCl₂ in the growth medium.

The Ca²⁺/calmodulin-dependent protein phosphatase calcineurin plays a critical role in maintaining intracellular ion homeostasis and cell integrity. Further, simultaneous loss of certain subunits of V-ATPase and calcineurin is synthetically lethal in *S. cerevisiae* [35, 36]. In agreement with the findings for *S. cerevisiae*, the *C. glabrata* $\Delta vph2$ mutant was unable to grow in the presence of the calcineurin inhibitor FK506 (Fig 3). In addition to fluconazole and voriconazole, the $\Delta vph2$ mutant displayed increased susceptibility to fenpropimorph, which inhibits C-8 sterol isomerase (*Erg2*) and C-14 sterol reductase (*Erg24*) in the ergosterol biosynthesis




Fig 3. Spot dilution assay. Serial 10-fold dilutions of logarithmic-phase cells of *C. glabrata* were spotted onto SC plates containing the indicated compounds at the specified concentrations. Plates were incubated at 30°C for 48 h and photographed. The images are representative of three independent replicate experiments. BPS, bathophenanthroline disulfonate; and DFO, desferrioxamine.

<https://doi.org/10.1371/journal.pone.0210883.g003>

pathway [37, 38], and amphotericin B, which directly targets ergosterol [39]. Finally, the $\Delta vph2$ mutant also exhibited growth defects under iron-limited conditions induced by the inclusion of the bacterial siderophore DFO or the Fe^{2+} -chelator BPS in the growth medium.

Loss of Vph2 results in reduced fungal virulence in a murine model of disseminated candidiasis

The effect of *VPH2* deletion on the virulence of *C. glabrata* was examined using a mouse model of disseminated candidiasis. No mice died prior to euthanasia in the experiments. Fungal burdens in the examined organs of immunocompetent mice infected with the $\Delta vph2$ mutant were significantly lower than those in mice infected with the wild-type or *VPH2*-reconstituted strains (Fig 4). This suggested that V-ATPase plays an important role in the virulence in *C. glabrata*.

Discussion

Overcoming the antifungal resistance of *C. glabrata* in the clinical setting is a pressing issue. In the current study, we demonstrated the synergistic effect of the V-ATPase inhibitor bafilomycin B₁ and azole antifungals against a *C. glabrata* wild-type strain. Azole antifungals exert an antifungal effect partly by impairing vacuolar acidification, since ergosterol is required for V-ATPase to function efficiently [28]. The concurrent disruption of ergosterol and V-ATPase was induced by exposing the $\Delta vph2$ mutant to ergosterol inhibitors, leading to the severe growth impairment of the $\Delta vph2$ mutant (Fig 3). Some *C. glabrata* $\Delta vph2$ phenotypes were anticipated based on the published findings in *S. cerevisiae* and *C. albicans*. However, in the current study, we demonstrated for the first time that the loss of Vph2 in *C. glabrata* results in a V-ATPase defect, which leads to impaired vacuolar pH homeostasis and increased sensitivity to a variety of environmental stresses, as well as attenuated virulence in mice. The growth defect of the $\Delta vph2$ mutant could contribute to the enhanced susceptibility to diverse drugs tested and decreased virulence.

The $\Delta vph2$ mutant was unable to grow under iron-limiting conditions. Requirement of V-ATPase for iron homeostasis was also demonstrated in *H. capsulatum* [19]. Iron acquisition and iron homeostasis are important virulence factors in pathogenic fungi. For example, *C. albicans* must obtain hemoglobin iron to survive under the iron-limiting conditions in host tissues, and functional V-ATPase is required for iron acquisition in the microorganism [40].




Fig 4. Fungal virulence in a mouse model of disseminated candidiasis. Eight-week-old female BALB/c mice were intravenously inoculated with 8×10^7 cells of each *C. glabrata* strain (wild-type, $n = 7$; $\Delta vph2$, $n = 9$; and $\Delta vph2 + VPH2$, $n = 8$; per experiment). The mice were sacrificed 7 d after inoculation and CFUs per organ in specific organs were determined. The geometric mean is shown as a bar. Data representative of two independent experiments are shown. The *C. glabrata* strains used were: wild-type (CBS138), filled circles; $\Delta vph2$ mutant, squares; and $VPH2$ -reconstituted strain, triangles. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ (Kruskal-Wallis test with Dunn's post-test).

<https://doi.org/10.1371/journal.pone.0210883.g004>

Targeting a conserved protein that plays an essential role in human and fungal cells is challenging as it entails averting host toxicity. For instance, V-ATPase is present in the renal tubules and osteoclasts in mammals, including human [8]. However, although V-ATPase is highly conserved in eukaryotes, some major differences between mammalian and fungal V-ATPases exist, particularly with respect to the isoform composition of subunits and in the regulation of complex disassembly [41–45]. The different numbers and types of isoforms have been developed for most subunits of the mammalian V-ATPase [7]. The sequence conservation between *S. cerevisiae* and human V-ATPase subunits is 51–60% similarity and 31–41% identity, depending on the subunit and isoform [44]. *C. glabrata VPH2* encodes a putative protein of 209 amino acids, with a molecular mass of 23.4 kDa. The deduced amino acid sequences of *C. glabrata VPH2* share 61.8% similarity and 41.9% identity with those of *S. cerevisiae VPH2* (NCBI Gene ID 853741, NCBI accession no. CAA81960), but only 32.6% similarity and 18.1% identity with those of a human homolog (TMEM199: NCBI Gene ID 147007, NCBI accession no. NP_689677) (S1 Fig). These different features could potentially be exploited to selectively target V-ATPase of pathogenic fungi.

In conclusion, in the current study, we provided evidence that disruption of *C. glabrata* V-ATPase function by deleting *VPH2* impairs the fungal response to various environmental stresses and results in the attenuation of virulence of this clinically important fungal pathogen, supporting the notion that V-ATPase is an attractive antifungal target.

Supporting information

S1 Fig. Sequence alignment of the deduced amino acids of *C. glabrata VPH2* with those of *S. cerevisiae VPH2* and a human homolog TMEM199. Identical and similar amino acids are

shown as darkly shaded and lightly shaded regions, respectively. GenBank accession number: *C. glabrata* VPH2, XP_448720; *S. cerevisiae* VPH2, CAA81960; and TMEM199, NP_689677. (TIF)

Author Contributions

Conceptualization: Taiga Miyazaki.

Data curation: Asuka Minematsu, Shintaro Shimamura, Hiroshi Nishikawa, Hironobu Nakayama.

Formal analysis: Asuka Minematsu.

Funding acquisition: Taiga Miyazaki, Shigeru Kohno, Hiroshi Mukae, Koichi Izumikawa.

Investigation: Asuka Minematsu.

Methodology: Asuka Minematsu, Taiga Miyazaki, Shintaro Shimamura, Hiroshi Nishikawa, Hironobu Nakayama, Takahiro Takazono, Tomomi Saijo, Kazuko Yamamoto, Yoshifumi Imamura, Katsunori Yanagihara.

Project administration: Taiga Miyazaki.

Supervision: Taiga Miyazaki, Shigeru Kohno, Hiroshi Mukae, Koichi Izumikawa.

Validation: Asuka Minematsu, Taiga Miyazaki, Hiroshi Nishikawa.

Visualization: Asuka Minematsu.

Writing – original draft: Asuka Minematsu, Taiga Miyazaki.

Writing – review & editing: Taiga Miyazaki, Hiroshi Mukae, Koichi Izumikawa.

References

1. Kullberg BJ, Arendrup MC. Invasive candidiasis. *N Engl J Med*. 2015; 373(15):1445–1456. <https://doi.org/10.1056/NEJMr1315399> PMID: 26444731
2. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in *Candida albicans* and emerging non-*albicans* *Candida* species. *Front Microbiol*. 2017; 7:2173. <https://doi.org/10.3389/fmicb.2016.02173> PMID: 28127295
3. Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. *Infect Drug Resist*. 2017; 10:249–259. <https://doi.org/10.2147/IDR.S124918> PMID: 28919789
4. Arendrup MC, Patterson TF. Multidrug-resistant *Candida*: epidemiology, molecular mechanisms, and treatment. *J Infect Dis*. 2017; 216(Suppl 3):S445–S451. <https://doi.org/10.1093/infdis/jix131> PMID: 28911043
5. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. *Lancet Infect Dis*. 2017; 17(12):e383–e392. [https://doi.org/10.1016/S1473-3099\(17\)30316-X](https://doi.org/10.1016/S1473-3099(17)30316-X) PMID: 28774698
6. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of *Candida glabrata*. *J Clin Microbiol*. 2012; 50(4):1199–1203. <https://doi.org/10.1128/JCM.06112-11> PMID: 22278842
7. Hayek SR, Lee SA, Parra KJ. Advances in targeting the vacuolar proton-translocating ATPase (V-ATPase) for anti-fungal therapy. *Front Pharmacol*. 2014; 5:4. <https://doi.org/10.3389/fphar.2014.00004> PMID: 24478704
8. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. *Nat Rev Mol Cell Biol*. 2007; 8(11):917–929. <https://doi.org/10.1038/nrm2272> PMID: 17912264
9. Kane PM. The where, when, and how of organelle acidification by the yeast vacuolar H⁺-ATPase. *Microbiol Mol Biol Rev*. 2006; 70(1):177–191. <https://doi.org/10.1128/MMBR.70.1.177-191.2006> PMID: 16524922

10. Bond S, Forgac M. The Ras/cAMP/protein kinase A pathway regulates glucose-dependent assembly of the vacuolar (H⁺)-ATPase in yeast. *J Biol Chem*. 2008; 283(52):36513–36521. <https://doi.org/10.1074/jbc.M805232200> PMID: 18936098
11. Graham LA, Stevens TH. Assembly of the yeast vacuolar proton-translocating ATPase. *J Bioenerg Biomembr*. 1999; 31(1):39–47. PMID: 10340847
12. Huss M, Vitavska O, Albertmelcher A, Bockelmann S, Nardmann C, Tabke K, et al. Vacuolar H⁺-ATPases: intra- and intermolecular interactions. *Eur J Cell Biol*. 2011; 90(9):688–695. <https://doi.org/10.1016/j.ejcb.2011.04.009> PMID: 21640428
13. Davis-Kaplan SR, Compton MA, Flannery AR, Ward DM, Kaplan J, Stevens TH, et al. PKR1 encodes an assembly factor for the yeast V-type ATPase. *J Biol Chem*. 2006; 281(42):32025–32035. <https://doi.org/10.1074/jbc.M606451200> PMID: 16926153
14. Graham LA, Hill KJ, Stevens TH. Assembly of the yeast vacuolar H⁺-ATPase occurs in the endoplasmic reticulum and requires a Vma12p/Vma22p assembly complex. *J Cell Biol*. 1998; 142(1):39–49. PMID: 9660861
15. Kane PM, Stevens TH. The long physiological reach of the yeast vacuolar H⁺-ATPase. *J Bioenerg Biomembr*. 2007; 39(5–6):415–421. <https://doi.org/10.1007/s10863-007-9112-z> PMID: 18000744
16. Hirata R, Umemoto N, Ho MN, Ohya Y, Stevens TH, Anraku Y. VMA12 is essential for assembly of the vacuolar H⁺-ATPase subunits onto the vacuolar membrane in *Saccharomyces cerevisiae*. *J Biol Chem*. 1993; 268(2):961–967. PMID: 8419376
17. Nishikawa H, Miyazaki T, Nakayama H, Minematsu A, Yamauchi S, Yamashita K, et al. Roles of vacuolar H⁺-ATPase in the oxidative stress response of *Candida glabrata*. *FEMS Yeast Res*. 2016; 16(5): pii: fow054. <https://doi.org/10.1093/femsyr/fow054> PMID: 27370212
18. Erickson T, Liu L, Gueyikian A, Zhu X, Gibbons J, Williamson PR. Multiple virulence factors of *Cryptococcus neoformans* are dependent on VPH1. *Mol Microbiol*. 2001; 42(4):1121–1131. PMID: 11737651
19. Hilty J, Smulian AG, Newman SL. The *Histoplasma capsulatum* vacuolar ATPase is required for iron homeostasis, intracellular replication in macrophages and virulence in a murine model of histoplasmosis. *Mol Microbiol*. 2008; 70(1):127–139. <https://doi.org/10.1111/j.1365-2958.2008.06395.x> PMID: 18699866
20. Patenaude C, Zhang Y, Cormack B, Köhler J, Rao R. Essential role for vacuolar acidification in *Candida albicans* virulence. *J Biol Chem*. 2013; 288(36):26256–26264. <https://doi.org/10.1074/jbc.M113.494815> PMID: 23884420
21. Poltermann S, Nguyen M, Günther J, Wendland J, Härtl A, Künkel W, et al. The putative vacuolar ATPase subunit Vma7p of *Candida albicans* is involved in vacuole acidification, hyphal development and virulence. *Microbiology*. 2005; 151(Pt 5):1645–1655. <https://doi.org/10.1099/mic.0.27505-0> PMID: 15870472
22. Dujon B, Sherman D, Fischer G, Durrens P, Casaregola S, Lafontaine I, et al. Genome evolution in yeasts. *Nature*. 2004; 430(6995):35–44. <https://doi.org/10.1038/nature02579> PMID: 15229592
23. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Wayne, PA.: Clinical and Laboratory Standards Institute; 2012.
24. Nagayoshi Y, Miyazaki T, Shimamura S, Nakayama H, Minematsu A, Yamauchi S, et al. Unexpected effects of azole transporter inhibitors on antifungal susceptibility in *Candida glabrata* and other pathogenic *Candida* species. *PLoS One*. 2017; 12(7):e0180990. <https://doi.org/10.1371/journal.pone.0180990> PMID: 28700656
25. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. *Antimicrob Agents Chemother*. 2004; 48(3):693–715. <https://doi.org/10.1128/AAC.48.3.693-715.2004> PMID: 14982754
26. Miyazaki T, Nakayama H, Nagayoshi Y, Kakeya H, Kohno S. Dissection of Ire1 functions reveals stress response mechanisms uniquely evolved in *Candida glabrata*. *PLoS Pathog*. 2013; 9(1):e1003160. <https://doi.org/10.1371/journal.ppat.1003160> PMID: 23382685
27. Johnson RM, Allen C, Melman SD, Waller A, Young SM, Sklar LA, et al. Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry. *Anal Biochem*. 2010; 398(2):203–211. <https://doi.org/10.1016/j.ab.2009.12.020> PMID: 20018164
28. Zhang YQ, Gamarra S, Garcia-Effron G, Park S, Perlin DS, Rao R. Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. *PLoS Pathog*. 2010; 6(6):e1000939. <https://doi.org/10.1371/journal.ppat.1000939> PMID: 20532216
29. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington DC: National Academy Press; 2011.

30. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. *Trends Microbiol.* 2003; 11(6):272–279. PMID: [12823944](#)
31. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. *Proc Natl Acad Sci U S A.* 1988; 85(21):7972–7976. PMID: [2973058](#)
32. Drose S, Bindseil KU, Bowman EJ, Siebers A, Zeeck A, Altendorf K. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. *Biochemistry.* 1993; 32(15):3902–3906. PMID: [8385991](#)
33. Bairwa G, Rasheed M, Taigwal R, Sahoo R, Kaur R. GPI (glycosylphosphatidylinositol)-linked aspartyl proteases regulate vacuole homeostasis in *Candida glabrata*. *Biochem J.* 2014; 458(2):323–334. <https://doi.org/10.1042/BJ20130757> PMID: [24341558](#)
34. Vida TA, Emr SD. A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast. *J Cell Biol.* 1995; 128(5):779–92. PMID: [7533169](#)
35. Garrett-Engele P, Moilanen B, Cyert MS. Calcineurin, the Ca²⁺/calmodulin-dependent protein phosphatase, is essential in yeast mutants with cell integrity defects and in mutants that lack a functional vacuolar H(+)-ATPase. *Mol Cell Biol.* 1995; 15(8):4103–4114. PMID: [7542741](#)
36. Hemenway CS, Dolinski K, Cardenas ME, Hiller MA, Jones EW, Heitman J. *vph6* mutants of *Saccharomyces cerevisiae* require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. *Genetics.* 1995; 141(3):833–844. PMID: [8582630](#)
37. Jia N, Arthington-Skaggs B, Lee W, Pierson CA, Lees ND, Eckstein J, et al. *Candida albicans* sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. *Antimicrob Agents Chemother.* 2002; 46(4):947–957. <https://doi.org/10.1128/AAC.46.4.947-957.2002> PMID: [11897574](#)
38. Marcireau C, Guilloton M, Karst F. *In vivo* effects of fenpropimorph on the yeast *Saccharomyces cerevisiae* and determination of the molecular basis of the antifungal property. *Antimicrob Agents Chemother.* 1990; 34(6):989–993. PMID: [2203312](#)
39. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, et al. Amphotericin primarily kills yeast by simply binding ergosterol. *Proc Natl Acad Sci U S A.* 2012; 109(7):2234–2239. <https://doi.org/10.1073/pnas.1117280109> PMID: [22308411](#)
40. Weissman Z, Shemer R, Conibear E, Kornitzer D. An endocytic mechanism for haemoglobin-iron acquisition in *Candida albicans*. *Mol Microbiol.* 2008; 69(1):201–217. <https://doi.org/10.1111/j.1365-2958.2008.06277.x> PMID: [18466294](#)
41. Finnigan GC, Hanson-Smith V, Stevens TH, Thornton JW. Evolution of increased complexity in a molecular machine. *Nature.* 2012; 481(7381):360–364. <https://doi.org/10.1038/nature10724> PMID: [22230956](#)
42. Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H⁺)-ATPases. *Arch Biochem Biophys.* 2008; 476(1):33–42. <https://doi.org/10.1016/j.abb.2008.03.025> PMID: [18406336](#)
43. Kane PM. Targeting reversible disassembly as a mechanism of controlling V-ATPase activity. *Curr Protein Pept Sci.* 2012; 13(2):117–123. PMID: [22044153](#)
44. Rahman S, Yamato I, Saijo S, Mizutani K, Ishizuka-Katsura Y, Ohsawa N, et al. Biochemical and biophysical properties of interactions between subunits of the peripheral stalk region of human V-ATPase. *PLoS One.* 2013; 8(2):e55704. <https://doi.org/10.1371/journal.pone.0055704> PMID: [23409023](#)
45. Toei M, Saum R, Forgac M. Regulation and isoform function of the V-ATPases. *Biochemistry.* 2010; 49(23):4715–4723. <https://doi.org/10.1021/bi100397s> PMID: [20450191](#)